Napactadine is a bicyclic antidepressant agent. It is a histamine-H1 receptor antagonist. Preliminary results indicated a marked improvement in depressive symptomalology within 7 days of treatment, as measured by the Hamilton depression scale. However, clinical studies were discontinued after chronic administration of napactadine because an elevation in liver enzyme levels was observed in some patients.

Disoxaril is the antipicornavirus drug. It is an isoxazole heterocyclic compound and a member of the antiviral series commonly referred to as WIN compounds. Disoxaril inhibits enterovirus replication by binding to the hydrophobic pocket within the VP1 coat protein, thus stabilizing the virion and blocking its uncoating. The amino acid sequence of a large VP1 196-258 peptide (disoxaril-binding region) of CVB1/RESISTANT was significantly different from that of the CVB1/SOF (sensitive). Crucially important changes in CVB1/RES were two point mutations, M213H and F237L, both in the ligand-binding pocket. Treatment with disoxaril in newborn mice infected with Coxsackie B1 virus, for 10 days post virus inoculation decreased the virus titer in the mouse brain till day 7.

ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine] is a potent cholinergic neuronal nicotinic acetylcholine receptor (nAChR) ligand with analgesic properties. ABT-594 binds alpha-4/ beta-2 neuronal nAChRs acting as an agonist. ABT-594 is studying for the treatment of diabetic peripheral neuropathic pain.

Losoxantrone is an anthrapyrazole that induces both single and double strand breaks in DNA and is a potent inhibitor of DNA synthesis. The drug is in clinical trials for the treatment of breast cancer and of prostate cancer that is refractory to androgen ablation. Acute toxicity is negligible. Losoxantrone may be less cardiotoxic than doxorubicin. Up to 40% of patients encounter alopecia. 3% of patients develop congestive heart failure. Losoxantrone had been in phase II clinical trial for the treatment of breast and prostate cancer. However, this development was discontinued.

Gadomelitol (P792, Vistarem) is a monogadolinated contrast agent for magnetic resonance imaging (MRI) that originally was developed as a blood pool agent with rapid clearance and mainly free renal elimination. Gadomelitol could provide information on the interstitial fluid pressure (negatively associated with disease-free survival in locally advanced cervical carcinoma) of cervical carcinoma xenografts. Due to its slow extravasation and high tumor residence time, gadomelitol may potentially be useful to improve characterization between benign versus malignant tumors using dynamic MRI.

Encyprate (MO-1255) is a unique drug in being inactive as an MAO inhibitor in vitro but very active in vivo. It most probably is converted by the body to ethyl-N-benzyl-N-cyclopropylcarbamate which is an active MAOI in vitro. I was studying in the treatment of depression.

Nifurmazole, a 5-nitrofuran derivative, is an antibacterial agent. It was used for controlling Salmonella choleraesuis in swine. The mode of action of 5-nitrofuran analogues is based on red-ox biotransformation. Nifurmazole is active against Trypanosoma equiperdum, Schizotrypanum cruzi and Trypanosoma gambiense. Nifurmazole was shown to be somewhat effective againstT. cruzi infection in mice.

Mopidralazine is slower in onset and longer lasting than hydralazine and is devoid of adrenergic system stimulation. Its antihypertensive action is mediated by arteriolar dilatation. In the rat, Mopidralazine is rapidly metabolized, mainly by pyrrole-ring opening and subsequent formation of a mesoionic 3-(1-pyridazinyl)pyridazine In dogs, oxidative cleavage of the morpholine ring has been found to be the primary metabolic attack. In a small clinical trial, Mopidralazine resulted in significant reductions in blood pressure, both supine and standing, which was maximal 4-8 h after dosing, with no additional orthostatic component.

Pibecarb is an antihemorrhagic and capillary protective agent.

Hoquizil, a phosphodiesterase inhibitor, was used as a bronchodilator agent. Information about the current use of this drug is not available.